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Abstract
Background Patientswith an IgG subclass deficiency (IgSD) ± specific polysaccharide antibody deficiency (SPAD) often present with
recurrent infections. Previous retrospective studies have shown that prophylactic antibiotics (PA) and immunoglobulin replacement
therapy (IRT) can both be effective in preventing these infections; however, this has not been confirmed in a prospective study.
Objective To compare the efficacy of PA and IRT in a randomized crossover trial.
Methods A total of 64 patients (55 adults and 9 children) were randomized (2:2) between two treatment arms. Treatment armA began
with 12 months of PA, and treatment arm B began with 12 months of IRT. After a 3-month bridging period with cotrimoxazole, the
treatment was switched to 12 months of IRT and PA, respectively. The efficacy (measured by the incidence of infections) and
proportion of related adverse events in the two arms were compared.
Results The overall efficacy of the two regimens did not differ (p = 0.58, two-sided Wilcoxon signed-rank test). A smaller proportion
of patients suffered a related adverse event while using PA (26.8% vs. 60.3%, p< 0.0003, chi-squared test). Patients with persistent
infections while using PA suffered fewer infections per year after switching to IRT (2.63 vs. 0.64, p< 0.01).
Conclusion We found comparable efficacy of IRT and PA in patients with IgSD ± SPAD. Patients with persistent infections
during treatment with PA had less infections after switching to IRT.
Clinical Implication Given the costs and associated side-effects of IRT, it should be reserved for patients with persistent infections
despite treatment with PA.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s10875-020-00841-3) contains supplementary
material, which is available to authorized users.
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PAD Primary antibody deficiency
PID primary immunodeficiencies
PLS-DA Partial least squares discriminant analysis
SPAD Specific polysaccharide antibody deficiency
URTI/LRTI Upper/lower respiratory tract infections
XLA X-linked agammaglobulinemia
Introduction
Low or absent levels of circulating specific antibodies are the
hallmark of primary antibody deficiencies (PADs), which
cover a spectrum of antibody deficiency syndromes ranging
from IgG subclass deficiency (IgSD) and impaired specific
polysaccharide antibody production to agammaglobulinemia
as the most severe antibody deficiency disease manifestation
[1–3]. PADs are the most common type of primary immuno-
deficiency (PID) with an estimated prevalence ranging from
2.0 to 2.5/10,000 in the USA, excluding patients with IgA
deficiency [4, 5]. For severe types of PAD such as common
variable immunodeficiency (CVID) and X-linked agamma-
globulinemia (XLA), evidence-based treatment guidelines in-
volving immunoglobulin replacement therapy (IRT) have
been developed [6–11]. In contrast, for the less severe forms
of PAD such as IgSD ± specific polysaccharide antibody de-
ficiency (SPAD), guidelines are lacking, and both prophylac-
tic antibiotics and IRT are used. Although the costs and pos-
sible side effects of these treatments differ significantly, stud-
ies that prospectively compare these two regimens have not
been published [8, 12, 13].
Patients with IgSD ± SPAD (in this study defined as
patients with incomplete antibody deficiency) present
with similar symptoms ranging from asymptomatic to re-
current upper and lower respiratory tract infections
(URTI/LRTI) [10, 14, 15]. Although there is no general
consensus regarding the treatment of these patients, mul-
tiple sources have advocated a step-up approach for the
prevention of infections [8, 13, 16]. As a first-line treat-
ment, additional vaccinations combined with increased
vigilance and appropriate antibiotic therapy in the case
of bacterial infections can lead to significant clinical im-
provement. In the absence of improvement, prophylactic
antibiotics (PA) are often used to reduce the number of
infections [17–19]. Patients with persistent bacterial infec-
tions despite PA can be treated with IRT to further reduce
the infectious burden [16, 17, 20–23].
Open, non-placebo-controlled studies have shown that
both PA and IRT can be effective in patients with IgSD
and SPAD. In one study, 22 patients with an IgG2/4 de-
ficiency and recurrent URTIs were treated with
cotrimoxazole for 12 months. Twelve of the 22 patients
remained symptomatic on antibiotics and were subse-
quently treated with IRT (intravenous immunoglobulin
[IVIG], 400 mg/kg) every 3 weeks. Their mean incidence
of URTIs decreased significantly after the introduction of
IRT [12]. In another study, 26 patients diagnosed with
chronic sinusitis and decreased serum levels of immuno-
globulin isotypes, IgSD and/or SPAD were followed pro-
spectively for 1 year on prophylactic antibiotics. Nineteen
of 26 patients (74%) had a > 50% reduction in sinusitis
episodes during the 12-month follow-up period [19]. A
third retrospective study showed that 22 patients with
IgSD and/or SPAD significantly improved after the intro-
duction of IRT with a significant reduction in the number
of infections, antibiotic use, and hospital admissions per
year during the 5-year follow-up period when compared
with the year prior to IRT [22]. These findings support the
notion that patients with less severe forms of PAD such as
IgSD ± SPAD who suffer from recurrent RTIs can benefit
from either PA or IRT. Recently, a fourth retrospective
study was published comparing PA (different types, N =
7) and IRT (N = 29) in children with SPAD. The authors
reported a comparable mean number of infections in pa-
tients on PA vs. IRT (2.86, SD: 2.73 vs. 4.44, SD: 4.74)
during the 1-year follow-up period; however, 15 patients
(23.1%) failed on PA and switched to IRT during the year
[24]. Moreover, the mean number of infections did not
decrease in patients who received a combination of PA
and IRT (N = 7) [24]. However, the numbers of patients
in most of these studies were small, and evidence that one
of these treatment modalities is truly superior to the other
is lacking because these therapies have not been com-
pared in a prospective randomized study with a larger
cohort. As IRT is an expensive therapy for which global
demand is increasing, it is important to establish which
patients benefit the most from this type of therapy [25].
We aimed to compare the efficacy and side effects of pro-
phylactic antibiotics vs. intravenous immunoglobulin therapy
in patients with IgG subclass deficiency ± specific polysac-





The trial (P06.233/P08.034) was designed as a multicenter,
randomized phase IV trial with a crossover design comparing
the use of PA vs. IRT among IgSD and SPAD patients with
recurrent infections. Block randomization was performed in a
2:2 ratio, dividing the participants between treatment arms A
and B. Treatment arm A consisted of 12 months of prophy-
lactic treatment with cotrimoxazole followed by a 3-month
bridging period in which cotrimoxazole was also used as a
prophylaxis, followed by 12 months of intravenous immuno-
globulins (IVIG) (Fig. 1). Treatment arm B began with a 12-
month period of IVIG followed by a 3-month washout period
(during which antibiotics were given) and a 12-month period
of prophylactic cotrimoxazole. A minimum of 45 participants
was required for the assessment of the primary endpoint (the
number of infections per patient per year). The Institutional
Review Board (IRB) of Leiden University Medical Center
operated as the central IRB that reviewed and approved this
study. All participants signed written informed consent prior
to participation in the study.
Objectives and Endpoints
The primary objective was to measure the difference in the
number of infections per patient per year between the two
treatment modalities. The secondary predefined endpoints
were a reduction in the total duration of infections, a reduction
in severe infections, fewer periods of fever, fewer hospital
admissions and days absent from school/work due to infec-
tions, and improvement in the Karnofsky performance skill
index during the study. The number and duration of infections
were reported by the treating physician and infections were
classified from mild to severe using predefined definitions
(Table S1).
The secondary objective was to assess side effects and
tolerability through the evaluation of laboratory variables
and (serious) adverse events. The intensity of adverse events
(AEs) was classified as mild, moderate, or severe (Table S2).
Moreover, as an exploratory objective, this study evaluated
possible discriminative variables that could identify patients
who benefit from IRT.
Eligibility
This study included patients > 5 years of age with an
established diagnosis of IgG1, IgG2, and/or IgG3 subclass
and/or anti-polysaccharide antibody deficiency from eight
(tertiary) hospitals in the Netherlands. IgSD was defined as
IgG1, IgG2, and/or IgG3 serum levels below the age-adjusted
lower reference range, which was determined on two occa-
sions. SPAD was defined as an insufficient increase in anti-
pneumococcal antibody formation for > 50% of the measured
serotypes after vaccination with a 23-valent polysaccharide
pneumococcal vaccine (Pneumo23). A sufficient increase in
anti-pneumococcal antibody formation was defined as a 4-
fold rise in antibody titers measured 3–5 weeks after vaccina-
tion or a serum titer > 1 mg/ml (or > 20 IU/L) after vaccina-
tion. In patients with a previous pneumococcal conjugate vac-
cination, only nonconjugate serotypes were considered. The
diagnosis of SPADwas excluded for patients with a protective
anti-pneumococcal antibody titer prior to vaccination. Other
inclusion criteria were a total serum IgG level > 4 g/L and at
least 2 physician-diagnosed infections in the 6 months prior to
inclusion in the study.
Participants were excluded if they were treated with any
other investigational drug within a week before entry into the
study, if they had a history of allergic reactions to
Fig. 1 Inclusion tree of the study;
67 patients were initially enrolled
of which 3 discontinued before
the start of the study. A total of 55
adults and 9 children were
included in the intention to treat
population. For the per-protocol
analysis, 52 adults and 9 children
were included of which data from
8 patients was partially censored
because they were treated with
IVIG in addition to antibiotic
prophylaxis or had no document-
ed intake of antibiotics for part of
the study period
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immunoglobulin treatment, if they had a progressive terminal
disease or active systemic disease, if they were pregnant, or if
they were known to have renal insufficiency.
Treatment Description
IVIG was infused every 3 weeks dosed at 600 mg/kg for
patients ≥ 18 years old; younger patients were given
800 mg/kg every 3 weeks. Nanogam® was used as the intra-
venous immunoglobulin product and was supplied by
Sanquin Plasma Products BV, Amsterdam, the Netherlands
[26]. Cotrimoxazole was used as an antibiotic prophylaxis,
following national guidelines in the Netherlands and based
on data from previous retrospective cohort studies, showing
that cotrimoxazole was effective against the most prevalent
bacteria causing respiratory tract infections in both PAD and
non-PAD patients [12, 27–30]. Cotrimoxazole was dosed
once daily at 160 mg trimethoprim/800 mg sulfamethoxazole
for participants ≥ 12 years old or above 40 kg body weight,
whereas younger participants were given 4 mg trimethoprim/
20 mg sulfamethoxazole per kg bodyweight. If patients had a
known intolerance for cotrimoxazole or if it was not tolerated
during the trial, azithromycin was given 3 days per week
dosed at 500 mg per day for participants > 18 years old or
10 mg per kg body weight for younger participants. Patients
who developed three or more respiratory tract infections dur-
ing one study period were switched to a combined regimen of
IRT and PA, dosed as previously described, after the third
infection.
Laboratory Variables
As secondary markers of efficacy, we performed lymphocyte
phenotyping (performed at the Medical Immunology and the
Immunodiagnostic Laboratory of the Erasmus MC) [31] and
mannose-binding lectin (MBL) genotyping and determined
the MBL concentration (performed at the Laboratory of
Blood Cell Research and Immunochemistry of Sanquin diag-
nostics, BV) at the start of the study. Moreover, leukocyte
counts, hemoglobin levels, hematocrit, platelet counts, and
potassium, alanine aminotransferase, aspartate aminotransfer-
ase, alkaline phosphatase, lactic dehydrogenase, serum creat-
inine, and antibody levels were measured at the start of the
study and once every 3 months thereafter.
Statistics
A minimum sample size of N = 35 was calculated prior to
initiation of the study to prove noninferiority with a standard
deviation of 2 and a noninferiority limit of 1.5 infections per
year (α = 0.05, 90% power) between the two treatment arms.
However, since a larger sample size was reached, this study
was powered to prove noninferiority within a limit of 1.2
infections per patient per year between the two treatment
arms. Baseline characteristics were summarized by age group,
and study outcomes were summarized by treatment arm with
participants classified according to the intention to treat (ITT)
principle. For the mean number of infections per patient per
year, the standard deviation was estimated and the difference
was analyzed with a two-sided Mann-Whitney U test. For
other endpoints, categorical outcomes were described using
proportions and compared between the arms using a Chi-
squared test. Outcomes were corrected for multiple compari-
sons using the Holms-Bonferroni approach. A Cox propor-
tional hazard model was used to compare the time to first
infection in both treatment groups. Moreover, a per-patient
analysis was performed using the reduction in infection rates
to define a subgroup of patients who might benefit from IRT;
a reduction of at least 1 infection per year was set as the cutoff.
Differences between baseline variables in patients with and
without persistent infections were further visualized by fitting
a hierarchal clustering model and by a supervised clustering
method (partial least squares discriminant analysis, PLS-DA)
using a one-component model. R Studio version 1.2.5019 and
SAS version 9.4 were used to analyze the data.
Results
Enrolled and Randomized Participants
A total of 67 patients from 8 centers were enrolled in the study
(Fig. 1) of whom 58 were adults and 9 were children. Three
participants discontinued before randomization (withdrawal
of informed consent), and hence, a total of 64 patients was
available for the intention to treat analysis. Data from three
adult participants were excluded from the per-protocol analy-
sis for the following reasons: insufficient data (N = 1), misdi-
agnosis (no PAD, N = 1), and no documented intake of study
medication (N = 1). Furthermore, data from 8 participants
were partially censored for the per-protocol analysis because
they were treated with IVIG in addition to antibiotic prophy-
laxis (N = 3 during IRT treatment and N = 5 during PA treat-
ment) or had no documented intake of antibiotics for part of
the study period.
Baseline Characteristics
Baseline characteristics and the results of blood counts, im-
munoglobulin levels, B cell maturation markers, specific an-
tibody titers, and MBL activity are presented in Table 1. After
correcting for multiple comparisons, only the IgG2 levels
were found to be significantly lower in children compared
with those in adults (p < 0.0001). This was anticipated because
the normal ranges for IgG2 are lower for children than for
adults [32]; children and adults were pooled in further
J Clin Immunol
analyses. The mean IgG trough level of participants receiving
IRT was 11.77 g/L (95% CI: 10.8–12.7). Mean levels of IgM
and IgA did not differ significantly between children and
adults included in this cohort.
Primary Outcome: Infection Prevention
A total of 64 participants were evaluable for the primary end-
point analysis (IRT N = 58, PA N = 56). A total of 19,618
treatment days were recorded for the IRT group vs. 20,256
for the PA group. There was no proof of statistically signifi-
cant superiority of either treatment arm with a mean of 1.76
(SD: 1.92) infections per patient per year in the IRT arm vs.
1.55 (SD: 1.94) in the PA arm (Table 2). In the IRT group,
76.4% of the infections were RTIs vs. 73.8% of those in the
PA group. Of all the participants, 70.7% in the IRT arm and
51.8% in the PA arm had at least one infection during the
intervention period. However, this was not found to be signif-
icant in a Cox proportional hazards model, although a trend
towards a longer infection free survival during PA treatment
Table 1 Baseline characteristics
of the adults and children
analyzed in the intention to treat
analysis. Mean values were
compared with a Mann-Whitney
U test. Single asterisk indicates
significance after correction for
multiple comparisons using the
Holms-Bonferroni method









Hemoglobin (mmol/L) 8.66 8.27 0.133
Leukocytes (10^9/L) 7.80 5.06 0.023
Thrombocytes (10^9/L) 259 265 0.858
Neutrophils (10^9/L) 5.18 9.22 0.015
Eosinophils (10^9/L) 0.13 0.29 0.206
Lymphocytes (10^9/L) 2.07 2.03 0.629
Monocytes (10^9/L) 0.54 0.31 0.009
IgG
Total IgG l 7.76 7.14 0.766
IgG1 5.12 6.05 0.143
IgG2 1.90 0.62 < 0.0001*
IgG3 0.27 0.33 0.638
IgG4 0.27 0.23 0.656
IgA 1.39 0.69 0.017
IgM 1.35 0.65 0.169
IgE (g/L) 88.7 120 0.150
CD19 (%) 11.4 11.3 0.492
CD27 (%) 33.7 17.6 0.028
CD21 (%) 85.8 88.7 0.467
CH50 (%) 107.6 102.3 0.507
AP50 (%) 94.3 66.5 0.265
MBL expression (mg/mL) 0.38 3.20 0.081
Low MBL expression (< 0.8) 21/55 2/9
MBL polymorphism in exon 1 15/55 3/9
MBL polymorphism in promotor 42/55 6/9
Low MBL expression + exon 1 Polymorphism 1/55 0/9
Low MBL expression + promoter polymorphism 2/55 0/9
Low MBL expression + exon 1 and promoter polymorphisms 13/55 2/9
IgSD immunoglobulin G subclass deficiency, SPAD specific polysaccharide antibody deficiency, Ig immuno-
globulin, CD cluster of differentiation, and MBL mannose-binding lectin
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could be identified in both treatment periods (p = 0.116 and
p = 0.138, Fig. 2). To evaluate the therapeutic potential of a
combined therapy with both IRT and PA, the censored data of
the 7 participants receiving a combination therapy was com-
pared with the study population; however, no significant re-
duction in the incidence of infection was found.
Secondary Outcome Parameters
To further quantify the effect of the treatments in both study
arms, secondary outcome measures were compared. The
mean total duration of infections per year and the number of
severe infections (Table 2), days off school/work, febrile ep-
isodes, and hospitalization admissions were analyzed
(Table 3); no significant differences were found. The mean
total duration of infections per patient per year was 24.6 days
(SD: 30.0 days) in the IRT group vs. 23.1 days (SD: 42.0 days)
in the PA group. The mean number of severe infections per
patient per year was 0.11 (SD: 0.60) in the IRT group vs. 0.09
(SD: 0.36) in the PA group. Respiratory tract infections were
the most commonly reported infection (68% of all infections)
and were equally reported in both treatment arms.
Predictors of Benefit from IRT
To evaluate the possibility of a subgroup of patients who
benefited from IRT over PA, a per-patient analysis was
performed. The reported infection rates were analyzed and
the reductions in infection rates were calculated. In this anal-
ysis, we identified 11/58 patients with a reduction of at least 1
infection per year when treated with IRT instead of antibiotics
(monotherapy, as prescribed in the treatment protocol). To
further characterize these participants, a PLS-DA was per-
formed on all baseline characteristics available. This analysis
yielded no markers that could identify this subgroup of pa-
tients who benefited from IRT over PA. Next, we analyzed the
number of infections during treatment with PA as a separate
variable, and found that patients who suffered ≥ 2 infections
during treatment with PA generally had a beneficial response
when switched to IRT. Specifically, the occurrence of ≥ 2
infections despite the use of PA monotherapy identified par-
ticipants who subsequently improved following a switch to
IRT monotherapy with 80% (CI: 44.4–97.5) sensitivity and
80.6% specificity (CI: 64.0–91.8). Moreover, most of these
infections (86%) were RTIs. In this subgroup of patients with
persistent infections despite PA, there was a significant
(p < 0.01) reduction in the mean number of RTIs from 2.64
(SD: 2.20) RTIs per patient per year to 0.64 (SD: 0.81) for
patients treated with IRT. Finally, we analyzed whether we
could identify characteristics that could distinguish patients
who had a reduction of at least 1 infection when treated with
PA instead of IRT (28/58), but none could be found.
Moreover, we found an absolute reduction in the mean num-
ber of airway infections per year in those who benefited from
Table 2 Primary outcomemeasures in the intention to treat (ITT) and the per-protocol set (PPS). Chi-squared tests orMann-WhitneyU tests were used
accordingly to calculate the p values; no significant differences were found
ITT PPS
IRT PA p value IRT PA p value
Number of patients All 58 56 57 54
Children 7 9 7 9
Adults 51 47 50 45
Number of treatment days Sum 19,618 20,256 19,228 19,495
Mean (SD) 338.2 (85.3) 361.7 (79.9) 337.3 (90.5) 361.0 (73.8)
Number of infections All 89 84 88 82
Children 4 10 4 10
Adults 85 74 84 72
Duration (n) Acute 84 75 83 73
Chronic 5 9 5 9
Intensity (n) Mild 48 49 48 47
Moderate 35 30 34 30
Severe 6 5 6 5
Patients suffering ≥ 1 infection (%) 41 (70.7%) 29 (51.8%) 0.09 40 (70.2%) 29 (53.7%) 0.15
Infections per patient per year (SD) 1.76 (1.92) 1.55 (1.94) 0.56 1.77 (1.94) 1.57 (1.90) 0.58
Severe infections per patient per year (SD) 0.11 (0.60) 0.09 (0.36) 0.83 0.11 (0.60) 0.09 (0.36) 0.83
Days of infection per patient year (SD) 24.6 (30.0) 23.1 (42.0) 0.83 24.6 (30.3) 23.7 (42.4) 0.85
ITT intention to treat, PPS per-protocol set, IRT immunoglobulin replacement therapy, PA prophylactic antibiotics, and SD standard deviation
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PA over IRT of 1.03, versus 2.0 in the patients who benefited
from IRT over PA (p = 0.051).
Tolerability of Medication in Both Treatment Arms
The key secondary objective of this study was to compare the
tolerability of PA and IRT by analyzing the proportion of
patients who suffered any adverse events (AE) that were pos-
sibly related to treatment. A total of 64 participants received at
least one dose of study medication and had reports of safety
measurements. Overall, 37 subjects (66.1%) experienced at
least one AE during PA treatment, while there were only 46
such subjects (79.3%) during IRT. The most commonly
reported AEs for both treatment arms were diarrhea, nausea,
fatigue, pyrexia, headache, and rash for both the total number
of AEs and the AEs possibly related to treatment (Table S3).
In total, 40 participants (62.5%) experienced at least one AE
that was at least potentially related to the study drug: 15 in the
PA arm (26.8%) and 35 in the IRT arm (60.3%, p = 0.0003,
Table 4). Patients treated with IRT experienced headache
more often than patients treated with PA (36.2% vs. 1.8%,
p < 0.0001). The intensity of the adverse events that were pos-
sibly related to treatment was lower in the PA arm than in the
IRT arm; 25% of patients in the PA arm had AEs of mild
intensity, 1.8% of patients had AEs of moderate intensity,
and 0% of patients had AEs of severe intensity vs. 53.4%,
Table 3 Secondary outcome measures in the intention to treat (ITT) and the per-protocol set (PPS). Chi-squared tests or Mann-Whitney U tests were
used accordingly to calculate p values
ITT PPS
IRT PA p value IRT PA p value
Total number of patients 58 56 57 54
Total number of infections 89 84 88 82
Days off work or school
Total number of days off work/school 120 65 90 65
Patients (%) with at least one day off work/school 7 (12.1%) 7 (12.5%) 0.94 6 (10.5%) 7 (13.0%) 0.61
Number of days off work/school per patient per year (mean ± SD) 2.3 (9.3) 1.2 (3.4) 0.41 1.6 (7.9) 1.2 (3.4) 0.73
Fever
Total number of fever events 21 24 21 22
Patients (%) experiencing at least one fever event 12 (20.7%) 13 (23.2%) 0.71 12 (21.1%) 13 (24.1%) 0.66
Number of fever events per patient per year (mean ± SD) 0.4 (1.2) 0.5 (1.0) 0.63 0.5 (1.2) 0.4 (1.0) 0.64
Hospitalization due to infection
Total number of hospital admissions due to infection 14 10 13 10
Total number of days in the hospital due to infection 112 81 89 81
Patients (%) with at least one hospital admission 6 (10.3%) 7 (12.5%) 0.65 5 (8.8%) 7 (13.0%) 0.37
Number of hospital admissions per patient per year 0.30 (1.10) 0.19 (0.58) 0.51 0.28 (1.10) 0.20 (0.59) 0.64
Average number of days in the hospital per person year (mean ± SD) 2.80 (10.11) 1.49 (4.22) 0.37 2.32 (9.51) 1.55 (4.29) 0.59
ITT intention to treat, PPS per protocol set, IRT immunoglobulin replacement therapy, and PA prophylactic antibiotics
Fig. 2 Kaplan-Meier curves for
the time to first infection for
treatment period 1 (left) and
treatment period 2 (right). There
was a trend towards a longer time
to the first infection for the anti-
biotics group, but this was not
statistically significant (p = 0.116
and p = 0.138, respectively, for
periods 1 and 2)
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19.0%, and 3.4% in the IRT arm, respectively (p = 0.002).
Most (60%) of the AEs reported in the IRT group were report-
ed during the first four infusions. Moreover, 8 patients (5 in
treatment arm a, 3 in treatment arm B) were treated with
azithromycin, due to known or acquired intolerability of
cotrimoxazole.
Overall, 13 serious adverse events (SAE) were reported by
7 participants (12.5%) during PA and 26 SAEs were reported
by 11 participants (19%) during IRT. Of these SAEs, 24 orig-
inated from infection-related events (N = 12 during PA and
N = 12 during IRT). One of the SAEs was identified as prob-
ably related to IRT. The patient was admitted to the hospital
with fever, lymphadenopathy, myalgia, arthralgia, malaise,
and leucopenia of unknown origin from which the patient
recovered after 36 days, during which IRT was continued.
Discussion
This multicenter, randomized, controlled crossover trial is the
first to analyze the efficacy of PA versus IRT in patients with
IgSD ± SPAD. Overall, our data did not demonstrate a signif-
icant difference in infection-related parameters between the
two regimens, and PA was better tolerated than IRT.
However, the subgroup of patients with persistent infections
despite treatment with PA had significantly fewer infections
when treated with IRT.
Overall, the data from this study are generalizable to other
patients with IgSD ± SPAD and recurrent infections, as trial
eligibility criteria allowed the participation by both children
and adults with IgSD, SPAD, or both, and children and adults
from both disease categories were included. Only four patients
were included that suffered specifically from SPAD, making
this study less generalizable for that patient group. However,
the mean infection rates reported were comparable with those
reported in two earlier studies, one in childrenwith SPAD [24]
and one in adults with IgSD and SPAD [22]. The current study
design, a randomized, controlled crossover trial, was selected
as the optimal design to show differences in the efficacy of
prophylactic treatment in a relatively rare disease where the
cohort sizes are expected to be small [33]. Both treatment arms
covered 12 months to avoid seasonal differences in infections.
To ensure that successive infections were equally weighted in
the analysis, the duration and severity of infections were in-
cluded in the analyses. Moreover, good compliance was
achieved as 53/64 patients completely adhered to the protocol,
resulting in sample sizes sufficient to perform a per-protocol
analysis.
The crossover design of the study allowed further study of
the potential benefit of IRT over PA. Using subgroup analysis,
we were able to define a subgroup of patients with persistent
infections despite PA treatment who benefited from switching
to IRT. This group had ≥ 2 infections per year despite treat-
ment with PA and showed a statistically significant (p < 0.01)
and clinically relevant reduction in infections after switching
to IRT. Apart from the persistence of infections while using
PA, we found no other (laboratory) parameters identifying
patients who would benefit from IRT over PA. Joud Hajjar
et al. showed that patients with persistent infections had lower
IgG titers than patients who were responsive to PA or IRT;
however, we could not replicate this result in our cohort [24].
We also analyzedMBL, asMBL deficiencywas hypothesized
to be only clinically relevant in patients with concurrent im-
mune deficiencies; however, we found no clinically relevant
effect of MBL deficiency on infections even in combination
with the antibody deficiencies studied in our protocol. Our
data suggest that an empirical step-up approach, beginning
with antibiotic prophylaxis and switching to IRT monothera-
py in response to persistent infections, is valid for the treat-
ment of IgSD ± SPAD. IRT reduced the infectious burden in
patients on PA who suffered from two or more infections in
56% of the cases.
Table 4 Total numbers and proportions of (serious) adverse events
among the patients in the antibiotics and IRT groups. Chi-squared tests
were used to calculate the p values. Single asterisk indicates significance
after correction for multiple comparisons using the Holms-Bonferroni
method. The total number of events and the number of related serious
events were lower in the antibiotics group
Statistic PA IRT p value































PA prophylactic antibiotics, IRT immunoglobulin replacement therapy, and AE adverse event
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The tolerability analyses of this study showed that more
AEs that were possibly related to treatment occurred in the
IRT group. However, the majority of these AEs occurred dur-
ing the initial IRT infusions, and most of these AEs were
transient, mild, and were well-known adverse reactions to
IVIG. It is known that the number of AEs decreases over time,
as dosage and infusion rate are adjusted based on their occur-
rence [34]. Moreover, the risk of AEs differed in the two study
arms, as patients with a known intolerability to cotrimoxazole
or who experienced side effects from antibiotics during the
study were administered an alternative drug (azithromycin
instead of cotrimoxazole), whereas the protocol for patients
on IRT did not include an option for a different type of IRT in
the study. Overall, 8 patients were treated with azithromycin
instead of cotrimoxazole, which may have caused a reduction
in AEs within the PA group.
The limitations of this study are similar to those of other
smaller randomized studies of rare diseases, which are often
constrained by recruitment challenges. First, during recruit-
ment, several study candidates chose not to participate in the
study, as they preferred to adhere to the treatment they cur-
rently received. It is not clear how many patients received no
treatment, PA, or IRT, and whether this may have introduced
selection bias. However, the study still had sufficient power to
show that there was no significant difference in the efficacy
between PA and IRT and was able to detect noninferiority
with a limit of 1.2 infections per patient per year. The study
was not sufficiently powered to detect a difference in the in-
fection free survival time between the two study arms, or to
draw any concrete conclusions for patients affected by SPAD
specifically. Second, the protocol described relatively high
substitution doses of IVIG, which were not always achieved.
However, it is known that the dose of IVIG is not a good
measure of effectivity and that IgG trough levels in combina-
tion with a reduced frequency of sinopulmonary infections are
recommended instead [9, 11]. In CVID, trough levels of 6–
8 g/L have been advised for the optimal prevention of infec-
tions; this was achieved in all patients who received IRT in
this study [35, 36]. Third, this study did not analyze the effect
of PA on antibiotic resistance. However, a recent systematic
review that studied the use of PA in patients with chronic
obstructive pulmonary disease found no direct evidence for
an increase in antibiotic resistance [37]. A recent study in
CVID patients confirmed this for azithromycin in PID patients
in Italy during a 3-year follow-up period [38]. However, these
findings might not be generalizable to other countries, since
antibiotic resistance is a multifactorial issue depending,
among others, on local resistance patterns and the extent of
local prescription protocols. Antibiotic resistance is a growing
problem that could represent a serious threat particularly in
immunodeficient patients who are more susceptible to infec-
tions [39, 40]. Finally, the results of this study might not be
replicable in a non-trial setting due to a possible difference in
patient compliance between the two regimens. Non-
compliance for oral medication has been extensively studied
in the past and up to 50% of patients have been reported as
non-compliant with (oral) medication [41]. Due to the nature
of administration regimens of IRT, involving day-care settings
or home administration requiring specialized personnel, being
treated with IRT, could counteract some of the hurdles pa-
tients experience in complying to prophylactic treatment [42].
In conclusion, we found that overall, prophylactic antibi-
otics and IRTwere equally efficient in preventing infections in
a cohort of patients with IgSD ± SPAD. However, a subgroup
of patients with persistent infections during treatment with PA
showed a significant reduction in infections after switching to
IRT. Future research should focus on identifying biomarkers
to better define this group.
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